AstraZeneca has unveiled a major new alliance with up-and-coming China’s CSPC Pharmaceuticals to discover and develop novel oral drug candidates, a collaboration which underscores the emergence of the country’s biopharma sector.
Key Takeaways
- AstraZeneca has signed a deal with China's CSPC Pharmaceuticals to use it AI drug discovery platform.
The deal announced on 13 June will see AstraZeneca pay CSPC $110m upfront to generate preclinical candidates to treat diseases...